Welcome to our dedicated page for Opus Genetics news (Ticker: IRD), a resource for investors and traders seeking the latest updates and insights on Opus Genetics stock.
Opus Genetics, Inc. (Nasdaq: IRD) is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), along with small-molecule therapies for other ophthalmic disorders. The IRD news feed for IRD on Stock Titan aggregates company-issued updates, press releases, and regulatory communications that describe the progress of these programs.
Readers following Opus Genetics news can expect coverage of clinical trial milestones for its lead gene therapy candidates, including OPGx-LCA5 for Leber congenital amaurosis type 5 and OPGx-BEST1 for BEST1-related retinal degeneration and Best disease. The company regularly reports on Phase 1/2 and planned pivotal trial activities, safety and efficacy observations, and feedback from the U.S. Food and Drug Administration, such as outcomes of Regenerative Medicine Advanced Therapy (RMAT) meetings and regulatory designations.
News items also highlight pipeline expansion and preclinical work in programs targeting genes such as RHO, CNGB1, RDH12, NMNAT1, and MERTK, as well as partnerships with patient advocacy groups that provide non-dilutive funding and community engagement in rare retinal diseases. In addition, Opus Genetics issues updates on its small-molecule program, Phentolamine Ophthalmic Solution 0.75%, including supplemental New Drug Application plans and Phase 3 trials in presbyopia and low-light visual disturbances following keratorefractive surgery.
Investors and observers can also find corporate and financing announcements, such as registered direct offerings, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and conference participation at healthcare and ophthalmology events. By reviewing the IRD news page, users can track how Opus Genetics describes the evolution of its ophthalmic gene therapy and drug development pipeline over time.
Opus Genetics (Nasdaq: IRD) has secured FDA agreement under Special Protocol Assessment (SPA) for its Phase 3 clinical trial of oral APX3330 in treating moderate to severe non-proliferative diabetic retinopathy (NPDR). The agreement confirms that the trial design and endpoints will support a New Drug Application submission.
The primary endpoint focuses on reducing 3-step or greater worsening on the binocular diabetic retinopathy severity scale compared to placebo. Previous Phase 2 ZETA-1 trial showed APX3330's potential to slow DR progression with a favorable safety profile. The company plans to seek partners for further development while focusing on gene therapy candidates for inherited retinal diseases.
Diabetic retinopathy affects approximately 10 million patients in the US and is the leading cause of blindness in working-age adults.
Opus Genetics (Nasdaq: IRD) will host a virtual key opinion leader (KOL) event on December 11, 2024, at 4:00 PM ET to present 6-month efficacy and safety data from its ongoing Phase 1/2 trial of OPGx-LCA5, a gene therapy for LCA5-associated inherited retinal disease.
The event will feature renowned experts including Jean Bennett, MD, PhD, Tomas Aleman, MD, Christine Kay, MD, and Arshad Khanani, MD, MA, FASRS. They will discuss patient-level data, unmet needs in LCA5-associated IRD, and future development steps.
Jean Bennett, MD, PhD, is an Emeritus Professor at the University of Pennsylvania and has extensive experience in gene therapy research. Tomas Aleman, MD, is a Research Professor at the same university with expertise in hereditary retinal degenerations. Christine Kay, MD, is a director at Vitreoretinal Associates, focusing on inherited retinal diseases. Arshad Khanani, MD, MA, FASRS, is the Managing Partner at Sierra Eye Associates and a Clinical Professor at the University of Nevada.
The event will conclude with a live Q&A session.
Opus Genetics reported Q3 2024 financial results following its October acquisition by Ocuphire Pharma. The combined company, now trading as IRD, has a pro forma cash balance of $37 million, expected to extend runway into 2026. Q3 revenue was $3.9 million, down from $11.9 million in Q3 2023. Net loss was $7.5 million ($0.29 per share) compared to net income of $5.6 million in Q3 2023. The company expects four clinical data readouts in 2025, including Phase 3 studies for Phentolamine Ophthalmic Solution and gene therapy trials.
Opus Genetics (Nasdaq: IRD) announced that its Board of Directors has approved an equity award for Dr. Benjamin Yerxa, Ph.D., the Company's newly appointed President, under the 2021 Inducement Plan. Dr. Yerxa received a time-based restricted stock unit award of 332,800 shares, which will vest in four equal annual installments from 2025 to 2028. Dr. Yerxa previously served as CEO and President of the predecessor company before its acquisition in October 2024. The award was approved in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement to his employment, effective November 7, 2024.